225 related articles for article (PubMed ID: 34552329)
1. Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial.
Qi L; Zhang Q; Zheng Z; Pei Z; Mao H; Jiang T; Kazei D; Kahler E; Huo Y
Vasc Health Risk Manag; 2021; 17():571-580. PubMed ID: 34552329
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.
Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD
J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795
[TBL] [Abstract][Full Text] [Related]
3. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
4. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
[TBL] [Abstract][Full Text] [Related]
6. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study.
Tatsuno I; Saito Y; Kudou K; Ootake J
J Clin Lipidol; 2013; 7(3):199-207. PubMed ID: 23725919
[TBL] [Abstract][Full Text] [Related]
8. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.
Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N
Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
11. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
Castaldo RS
Postgrad Med; 2014 May; 126(3):268-73. PubMed ID: 24977343
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
13. Effects of Xuezhitong in Patients with Hypertriglyceridemia: a Multicentre, Randomized, Double-Blind, Double Simulation, Positive Drug and Placebo Parallel Control Study.
Jia W; Li Y; Wan J; Cui X; Lu J; Liu J; Li D; Li L; Zou T; Ding J; Lin Q
Cardiovasc Drugs Ther; 2020 Aug; 34(4):525-534. PubMed ID: 32206987
[TBL] [Abstract][Full Text] [Related]
14. Icosapent ethyl for treatment of elevated triglyceride levels.
Nelson SD; Munger MA
Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
Tatsuno I; Saito Y; Kudou K; Ootake J
J Clin Lipidol; 2013; 7(6):615-25. PubMed ID: 24314359
[TBL] [Abstract][Full Text] [Related]
16. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
Bays HE; Hallén J; Vige R; Fraser D; Zhou R; Hustvedt SO; Orloff DG; Kastelein JJ
J Clin Lipidol; 2016; 10(1):181-91.e1-2. PubMed ID: 26892135
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
[TBL] [Abstract][Full Text] [Related]
18. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
Bays HE; Ballantyne CM; Kastelein JJ; Isaacsohn JL; Braeckman RA; Soni PN
Am J Cardiol; 2011 Sep; 108(5):682-90. PubMed ID: 21683321
[TBL] [Abstract][Full Text] [Related]
19. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
20. Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy.
Glueck CJ; Khan N; Riaz M; Padda J; Khan Z; Wang P
Lipids Health Dis; 2012 Oct; 11():143. PubMed ID: 23110706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
